Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0
|
作者：
Prezotti, A. [1 ,2 ]
Montalvao, S. [1 ]
Marques, A. [3 ]
Ferreira, C. [4 ]
Oliveira, L. [5 ]
Villaca, P. [6 ]
Ferreira Filho, L. [7 ]
Lorenzato, C. [8 ]
Medina, S. [1 ]
Araujo, F. [9 ]
Ozelo, M. [1 ]
机构：
[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil
[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil
[3] HEMORIO, Hematol, Rio De Janeiro, Brazil
[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil
[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil
[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil
[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil
[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil
[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO286-MON
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [1] INHIBITOR QUESTIONS - PLASMA-DERIVED FACTOR-VIII AND RECOMBINANT FACTOR-VIII
    BRAY, G
    ANNALS OF HEMATOLOGY, 1994, 68 : S29 - S34
  • [2] SIMILAR NEUTRALIZATION OF RECOMBINANT FACTOR-VIII (RFVIII) AND NORMAL PLASMA BY FACTOR-VIII INHIBITOR PLASMA
    ABILDGAARD, CF
    HARRISON, J
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1168 - 1168
  • [3] Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates
    Lin, Y
    Yang, X
    Chevrier, MC
    Craven, S
    Barrowcliffe, TW
    Lemieux, R
    Ofosu, FA
    HAEMOPHILIA, 2004, 10 (05) : 459 - 469
  • [4] Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review
    Iorio, A.
    Halimeh, S.
    Goldenberg, N.
    Kenet, G.
    Young, G.
    Brandao, L.
    HAEMOPHILIA, 2010, 16 : 74 - 74
  • [5] Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction
    Dias, Maise Moreira
    Camelo, Ricardo Mesquita
    de Magalhaes, Laura Peixoto
    Jardim, Leticia Lemos
    de Oliveira, Andrea Goncalves
    de Albuquerque Ribeiro, Rosangela
    Franco, Vivian Karla Brognoli
    de Araujo Callado, Fabia Michelle Rodrigues
    Lorenzato, Claudia Santos
    Rezende, Suely Meireles
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2024, 41 (01) : 74 - 80
  • [6] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [7] Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review
    Iorio, A.
    Halimeh, S.
    Bidlingmaier, C.
    Ettingshausen, C. E.
    Gringeri, A.
    Holzhauer, S.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 (02) : 410 - 410
  • [8] RELATION OF ACTIVATED FACTOR-VIII TO THE POTENCY IN FACTOR-VIII CONCENTRATES, COMPARISON OF PLASMA-DERIVED AN RECOMBINANT FACTOR-VIII
    MINAMIYAMA, T
    ITO, Y
    OGURI, S
    KOBAYASHI, K
    TAKEDA, M
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 942 - 942
  • [9] Trial Results Reveal Greater Risk of Inhibitor Formation in Patients With Hemophilia A Receiving Recombinant Factor VIII Than in Patients Receiving Plasma-Derived Factor VIII
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 20 - 21
  • [10] Factor VIII safety: plasma-derived versus recombinant products
    Gringeri, Alessandro
    BLOOD TRANSFUSION, 2011, 9 (04) : 366 - 370
12345